- Home
- PSFE vs EVMN Comparison
PSFE vs EVMN Comparison
Compare PSFE & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSFE | EVMN |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.3M | 241.3M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PSFE | EVMN |
|---|---|---|
| Price | $5.72 | $5.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $8.50 | ★ $22.33 |
| AVG Volume (30 Days) | 302.6K | ★ 816.5K |
| Earning Date | 11-12-2026 | 11-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $6.51 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $5.35 | $6.02 |
| 52 Week High | $12.95 | $33.20 |
Technical Indicators
Market Signals| Indicator | PSFE | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 17.99 |
| Support Level | $5.35 | N/A |
| Resistance Level | $6.83 | $13.35 |
| Average True Range (ATR) | 0.29 | 0.47 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 28.00 | 1.31 |
Price Performance
Historical ComparisonAbout PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company's reportable segments are Merchant Solutions and Digital Wallets. The Merchant Solutions segment, which derives maximum revenue, services markets in North America, Canada and Europe. The Digital Wallets segment services markets in Europe, UK, North America and Latin America. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.